Successful treatment of metastatic vulvar malignant melanoma with toripalimab: A rare case report and review of the literature. Issue 36 (9th September 2022)

• Record Type: Journal Article
• Authors: Li, Yi-Hui; Zhou, Yang; Zhang, Guang-Ju; Wang, Yu-Wei; Wang, Jian-Gong; Wang, Xiao-Hong; Li, Yu-Feng
• Is Part Of: Medicine. Volume 101:Issue 36(2022)
• Page Start: e30239
• Publication Date: 2022-09-09
• Subjects: combination chemotherapy -- immunotherapy -- metastatic vulvar malignant melanoma -- toripalimab; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000030239
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Rationale: Vulvar melanoma is a rare and aggressive tumor with a high risk of local recurrence and distant metastasis. The prognosis is poor with a 5-year overall survival rate of only 46.6%. Management of vulvar melanoma remains a clinical challenge. Recent evidences have shown that immune checkpoint inhibitors are effective in the treatment of vulvar melanoma. Patient concerns and diagnoses: A 63-year-old woman with vulvar malignant melanoma suffered inguinal lymph node metastasis after vulvectomy and chemotherapy. She underwent inguinal lymph node dissection and inguinal radiotherapy. The tumor progressed again and she received immunotherapy. Interventions: The tumor progressed again, and she was admitted to our hospital and received toripalimab combined with apatinib and abraxane. Outcomes: After 6 cycles of immunotherapy, the efficacy achieved partial remission. And with toripalimab as maintenance therapy, the patient achieved durable antitumor efficacy and good safety. Lessons: In this rare case, the patient with metastatic vulvar malignant melanoma had durable antitumor efficacy and good safety when receiving toripalimab.